MissionIR Articles
-
MissionIRNewsBreaks – CYBIN Inc. Completes Reverse Takeover Transaction
CYBIN (formerly Clarmin Explorations Inc.), a life sciences company initially focused on psychedelic pharmaceutical therapies, on Thursday announced it has completed its previously disclosed reverse takeover of Clarmin Explorations Inc. per the terms of an…
-
MissionIRNewsBreaks – Cybin Corp. Paves Path to Profitability with Health-Care Veteran at the Helm
Cybin Corp., a Canada-based, life-science company advancing psychedelic pharmaceuticals, recently announced the appointment of Doug Drysdale as its CEO (https://ibn.fm/UTTdr). Drysdale, named an Ernst and Young Entrepreneur of the Year in 2012, brings more than…
-
CYBIN Corp. Set to Benefit from Growing Research, Interest in Psychedelics
Backed by an anonymous donor, Berkeley launches a center for psychedelic science and public education Berkley follows examples of other notable universities such as Johns Hopkins in Maryland, Imperial College in London, and Canadian Centre…
-
Cybin Corp. Appoints New CEO with Impressive Health-Care Expertise
Cybin appoints health-care expert Doug Drysdale as new CEO. Company confident that his extensive health-care sector background, international company management skills will strengthen Cybin partnerships. New CEO says business model, talented management team positions company…
-
MissionIRNewsBreaks – Cybin Corp. Holds Distinct Strength in Psychedelics Space
Cybin Corp., a Canada-based, life-science company, is focused on the development of mushroom-derived psychedelic pharmaceuticals and nonpsychedelic nutraceutical products. The company is positioning as countries around the world become increasingly accepting of psilocybin’s use in…
-
MissionIRNewsBreaks – Cybin Corp. CEO Eyes Opportunity in Psychedelics Space, Organic IP Expansion
Cybin Corp., a Canada-based, life-science company developing mushroom-derived psychedelic pharmaceuticals and nonpsychedelic nutraceutical products, recently announced the appointment of Doug Drysdale as the company’s chief executive officer. Well recognized in the pharmaceutical space, Drysdale brings…
-
MissionIRNewsBreaks – Cybin Corp. Leverages Two-Pronged Approach to Target Psychedelic, Nutraceutical Sectors
Cybin Corp., a Canada-based life-science company, looks to benefit from its growing footprint in two billion-dollar markets: nutraceuticals and psychedelic drugs. Both sectors are projected to see significant growth in the coming years. The global…
-
United Bid to Liberalize Use of Psilocybin Strengthens
Leading UK scientists, policy group call for rescheduling of psilocybin amid looming mental health crisis Sent to the Home Office with statements of support from leading scientists, paper urges for psilocybin use on a research-only…
-
Cybin Corp. New CEO Set to Pave Path to Profitability, Grow IP Portfolio Organically
Cybin announces appointment of established pharma industry figure as new CEO Drysdale leverages 30 years of leadership, entrepreneurial experience in life-science space Announcement comes as Cybin sets out on path to profitability Cybin Corp., an…
-
Cybin Corp. Leads Out in Growing Billion-Dollar Nutraceutical, Psychedelic Markets
Global nutraceutical market valued at $ 382.51 billion; psychedelic drugs market to reach $6.85 billion Cybin deploys two-pronged approach covering both psychedelic pharmaceutical and nutraceutical segments As psilocybin continues to prove effective in treating mental…
-
MissionIRNewsBreaks – Cybin Corp. CEO Discusses Milestones, Goals and Momentum in Exciting Emerging Industry
Cybin, a life-sciences company focused on advancing psychedelic and nutraceutical-based products, today announced that its CEO, Doug Drysdale, is featured in an exclusive audio interview with NetworkNewsWire (“NNW”) – a financial news and content distribution…
-
MissionIRNewsBreaks – Cybin Corp. Focused on Advancing New Products Amid Positive Research in Psychedelics
Cybin Corp., an exemplary Canada-based, life-science company focused on the development of pharmaceutical-grade psilocybin products, is at the forefront of change in an era open to exploring psychedelic treatment options where big pharma has failed.…
-
MissionIRNewsBreaks — Cybin Corp. Names Health-Care, M&A Expert as New Chief Executive Officer
Cybin Corp., a life-sciences company advancing psychedelic pharmaceuticals, has announced that Doug Drysdale has been appointed as CEO. With more than three decades of experience, Drysdale brings invaluable insight and expertise to his new role.…
-
Cybin Corp. at Forefront of Change in Psilocybin-Based Treatments
Company focused on furthering R&D of psilocybin-based medications Cybin believes psychedelic substances derived from mushrooms can work as boosters for brain Psilocybin shows promise for an array of mental health issues Cybin Corp. is a…
-
MissionIRNewsBreaks – Cybin Corp. Poised Amid Groundbreaking Decision to Allow Psilocybin Therapy
Cybin Corp., an exemplary Canada-based life-science company focused on the development of pharmaceutical-grade psilocybin products, appears ideally positioned to leverage a milestone moment. Canada’s Minister of Health, the Honourable Patty Hajdu, recently approved the use…
-
MissionIRNewsBreaks – Cybin Corp. Partners with IntelGenx to Develop Efficient Delivery Method for Pharmaceutical-Grade Psilocybin
Cybin Corp. recently announced its entry into a feasibility agreement with IntelGenx Corp., a leading drug-delivery company focused on the development and manufacturing of pharmaceutical delivery films (http://ibn.fm/TZeVy). Under the agreement, the two companies will collaborate…
-
Cybin Corp. Ideally Positioned as Landmark Decision Regarding Psilocybin Therapy Could Spark Increased Interest, Use
Canada’s Minister of Health approves the use of psilocybin therapy in end-of-life care of four Canadians battling incurable cancer The Decision marks first legal, medical exemptions for psilocybin use in Canada since the compound became…
-
Cybin Corp. Enters Feasibility Agreement to Develop Fast-Acting Psilocybin Film
Agreement with leading drug-delivery company outlines plans to develop fast-acting, orally dissolving film for delivery of pharmaceutical-grade psilocybin Cybin CEO notes that systemic bioavailability of film is projected to be high Cybin focused on developing…
-
MissionIRNewsBreaks — Cybin Calls Approval for Psilocybin Therapy in Palliative Care Treatment a ‘Watershed Moment’
Cybin Corp., Canada’s leading-edge mushroom life-sciences company, has noted its strong support for TheraPsil, a nonprofit coalition that advocates for legal, Special Access Programme (“SAP”) access to psilocybin therapy for palliative care of Canadians. The…
-
MissionIRNewsBreaks – Cybin Corp. Positioned in Shifting Trend Toward Psilocybin
Cybin Corp., Canada’s premier mushroom life-sciences company focused on advancing psychedelic and nutraceutical-based products, looks to be at the right place at the right time during a shifting trend toward psilocybin. Highlighting this shift, TheraPsil,…
Search Articles
Latest Articles
- BluSky AI Inc. (BSAI): Democratizing AI Through Modular Infrastructure and a New Neocloud That Scales from Startup to Enterprise
- MissionIRNewsBreaks – Solowin Holdings (NASDAQ: SWIN) Integrates Chainlink Data Services Into Tokenized Money Market Fund
- Brera Holdings PLC (NASDAQ: BREA) Gains Outperform Rating from PartnerCap Securities, Price Target Set at $11.50
- MissionIRNewsBreaks – Lantern Pharma Inc. (NASDAQ: LTRN) Advances Predictive Power in Cancer Drug Development
- MissionIRNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Positioned to Drive RapidSX(TM) Toward Commercial Launch